Efficacy and Tolerance of Vascular Electrical Stimulation Therapy in the Management of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: A Phase II Single-Centre Randomized Study in Ivory Coast
Table 4
Multivariate analysis of severe crisis elimination time (time to VAS > 2) and total crisis elimination time (VAS = 0) (Cox proportional hazards model).
Variable
Severe crisis elimination time, h (VAS ≤ 2)
Total crisis elimination time, h (VAS = 0)
HR (95% CI)
HR (95% CI)
Male gender
1.53 (0.45–5.20)
0.491 NS
7.21 (1.89–27.48)
0.004 S
Age, years
15–25
1
1
25–35
0.38 (0.08–1.85)
0.232 NS
0.83 (0.16–4.40)
0.830 NS
>35
0.69 (0.07–6.89)
0.756 NS
0.99 (0.14–7.02)
<0.999 NS
VAS at h0 = 10 phenotype
0.31 (0.09–1.07)
0.064 NS
1.37 (0.46–4.08)
0.574 NS
SAFA2
1
1
SC
0.21 (0.01–5.71)
0.354 NS
1.75 (0.07–44.47)
0.734 NS
SS
0.03 (0.01–2.08)
0.043 S
0.20 (0.01–10.03)
0.419 NS
SFA2
0.10 (0.01–9.22)
0.324 NS
2.73 (0.04–198.43
0.646 NS
CRP > 12 Hb
1.05 (0.33–33.01)
0.253 NS
1.40 (0.44–4.47)
0.566 NS
>10
1
1
8–10
7.78 (0.84–72.00)
0.071 NS
6.53 (0.66–65.10)
0.109 NS
<8
3.62 (0.40–33.01)
0.253 NS
1.19 (0.16–8.63)
0.863 NS
WBC
>15
1
1
10–15
0.59 (0.10–3.33)
0.549 NS
1.50 (0.32–7.09)
0.609 NS
<10
2.22 (0.45–10.99)
0.329 NS
0.59 (0.10–3.53)
0.567 NS
Arm
Group 0
1
1
Group 1
14.40 (2.11–98.47)
0.007 S
27.44 (4.63–162.76)
<0.001 S
Group 2
30.79 (4.51–210.06)
<0.001 S
58.05 (6.51–517.68)
<0.001 S
CRP, C-reactive protein; CI, confidence interval; h, hours; Hb, haemoglobin; HR, hazard ratio; NS, not significant; S, significant; VAS, visual analogue score; WBC, white blood cell; , value with significance set at less than 0.05. Bold values imply that the difference of severe crisis elimination observed between group 1 and group 0, and group 2 and group 0 is statistically significant.
